医学
需要伤害的数量
血管生成
内科学
心脏病学
荟萃分析
药理学
相对风险
需要治疗的数量
置信区间
作者
Husam Abdel‐Qadir,Josee-Lyne Ethier,Douglas S. Lee,Paaladinesh Thavendiranathan,Eitan Amir
标识
DOI:10.1016/j.ctrv.2016.12.002
摘要
Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors (anti-VEGF antibodies or decoy receptors), small molecule agents have higher risk due to their less specific mechanism. Methods We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for phase III randomised controlled trials comparing angiogenesis inhibitor-based therapy to other systemic therapy. Outcomes evaluated were hypertension, severe hypertension, cardiac dysfunction, congestive heart failure, cardiac ischemia, arterial thromboembolism, venous thromboembolism, and fatal cardiovascular events. Data were pooled using Mantel-Haenszel random effects method to generate odds ratios (OR). Results We identified 77 studies meeting inclusion criteria. Compared to routine care, angiogenesis inhibitors were associated with a higher risk of hypertension (OR 5.28 [4.53–6.15], number needed to harm [NNH] 6), severe hypertension (OR 5.59 [4.67–6.69], NNH 17), cardiac ischemia (OR 2.83 [1.72–4.65], NNH 85) and cardiac dysfunction (OR 1.35 [1.06–1.70], NNH 139). VEGF inhibitors were associated with an increased risk of arterial thromboembolism (OR 1.52 [1.17–1.98], NNH 141). No significant interaction was observed between the two drug subgroups for any outcomes. We identified no significant increase in the risk of the other outcomes evaluated. Conclusion Angiogenesis inhibitors increase the risk of hypertension, arterial thromboembolism, cardiac ischemia and cardiac dysfunction. There was no significant difference in cardiovascular risk between direct VEGF inhibitors and small molecule agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI